News & Insights

Gunderson Dettmer represented client Brightseed, a San Francisco-based developer of plant nutrient technology, in its $68 million Series B financing led by Temasek.

Gunderson Dettmer represented client Tarsus Pharmaceuticals, a biopharmaceutical company, in its upsized underwritten public offering of 5,600,000 shares of common stock at a public offering price of $13.50 per share which represents $75.6 million of common stock.

Gunderson Dettmer and Skadden are advising Anaplan, Inc. ("Anaplan"), provider of a leading cloud-native platform for orchestrating business performance, which yesterday announced that it has entered into a definitive agreement to be acquired by Thoma Bravo, a leading software investment firm, for $66.00 per share in an all-cash transaction valued at approximately $10.7 billion.